You are here:

Philae Pharmaceuticals

Back to overview

The first medical condition that Philae will target is Epidermolysis Bullosa (EB), a very rare but lethal disorder for which there is presently no treatment or cure. Patients with EB are known as ‘butterfly children’ because their skin is as fragile as a butterfly’s wings. The slightest amount of contact or friction can cause serious damage to their skin.

About Philae Pharmaceuticals

Philae Pharmaceuticals was founded by the late Professor Marcel Jonkman, previously Head of Dermatology at UMCG, Dick Kellogg, Emeritus Professor of Organic Chemistry, and Dr Reinier Schwietert, Pharmacologist.

Philae Pharmaceuticals belongs to the fund:

Pharma Connect Capital">

Investment fund Pharma Connect Capital (PCC) invests in very early-stage medicine development, drug delivery and biomarkers from the High Throughput Screening phase up to Phase 1 (sometimes Phase 2) and other projects...

View all the funds from the IFG

Cottonwood Technology Fund is an early stage fund that invests in deeptech/hard science startups with patented disruptiv...


CapitalT is a (pre-)seed fund that invests in companies which use AI to solve real world problems in climate tech, educa...